Meeting
2023 ASCO Annual Meeting
Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.
Authors
Haris Ali
City of Hope, Duarte, CA
Haris Ali , Ashwin Kishtagari , Keri Renee Maher , Sanjay Mohan , Josef T. Prchal , Xulong Wang , Kamal Chamoun , Srinivas Kiran Tantravahi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT04562389
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7063)
DOI
10.1200/JCO.2023.41.16_suppl.7063
Abstract #
7063
Poster Bd #
193
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.
First Author: Pankit Vachhani
Poster
2022 ASCO Annual Meeting
Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
First Author: Francesco Passamonti
Poster
2023 ASCO Annual Meeting
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
First Author: Aaron Thomas Gerds
Poster
2023 ASCO Annual Meeting
Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).
First Author: Prithviraj Bose